Ocuphire Pharma Announces Acquisition of Opus Genetics
The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs.
Ocuphire Pharma | 24/10/2024 | By Aishwarya | 267
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy